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Familial hemiplegic migraine (FHM; OMIM 141500) is a
rare hereditary subtype of migraine with aura. It is typi-
cally accompanied by hemiparesis and a variety of
neurological symptoms that may include both visual and
motor sensory disturbances (Olesen, 2004; Ophoff,
Terwindt, Frants, & Ferrari, 1998). The prevalence of this
disease has been estimated at around 0.01% in European
populations, with familial FHM accounting for half the
incidence rate. A sex ratio of three affected females to
every one male has also been recorded, hence women are
three times more likely to suffer from FHM than their
male counterparts (Thomsen et al., 2002). FHM is autoso-
mally dominantly inherited but shows variable
expressivity and genetic heterogeneity with 70% to 90%
penetrance (Rothner, 2001). In most cases, the phenotype
is severe as a result of neural disturbances and, in rare
cases, can be fatal after minor head traumas (Curtain,
Smith, Ovcaric, M, & Griffiths, 2006; Kors et al., 2001).
Due to the strong genetic component of FHM, it has
become a favorable target for the study of genes involved
in migraine pathogenesis (Colson, Fernandez, Lea, &
Griffiths, 2007).
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Three main genes have been implicated in the patho-
genesis of  FHM, namely CACNA1A (P/Q calcium
channel), ATP1A2 (P-type Na+/K+ ATPase), and SCN1A
(Na+ channel α subunit), with a possibility of a fourth
locus at 14q32 (Cuenca-León et al., 2008). This paper
highlights the discovery of a novel mutation and the
detection of a number of variants in the CACNA1A gene.
Mutations in the calcium channel gene, CACNA1A,
located on chromosome 19p13 have been linked to FHM1
in a number of family studies (Ophoff et al., 1996).
Currently, 21 different missense mutations that cause
FHM1 have been identified in the CACNA1A gene (de
Vries, Frants, Ferrari, & van den Maagdenberg, 2009). It is
estimated that CACNA1A mutations account for 50% of
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Familial hemiplegic migraine (FHM) is a rare autosomal dominant subtype of migraine with aura. It is divided
into three subtypes FHM1, FHM2 and FHM3, which are caused by mutations in the CACNA1A, ATP1A2 and
SCN1A genes respectively. As part of a regular diagnostic service, we investigated 168 patients with FHM
symptoms. Samples were tested for mutations contained within the CACNA1A gene. Some tested samples
(4.43%) showed an FHM1 mutation, with five of the mutations found in exon 5, one mutation in exon 16 and
one in exon 17. Four polymorphisms were also detected, one of which occurred in a large percentage of
samples (14.88%). The exon 16 2094G>A polymorphism, however, has been found to occur in healthy
Caucasian control populations up to a frequency of 16% and is not considered to be significantly associated
with FHM. A finding of significance, found in a single patient, was the detection of a novel mutation in exon 5
that results in a P225H change. The affected individual was an 8-year-old female. The exact phenotypic effect of
this mutation is unknown, and further studies are needed to understand the pathophysiology of this mutation in
FHM1. New information will allow for diagnostic procedures to be constantly updated, thus improving accuracy
of diagnosis. It is possible that new information will also aid the development of new therapeutic agents for the
treatment of FHM.
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FHM patients, and that it is this gene that is responsible
for the majority of FHM cases (Wieser, 2003). CACNA1A
encodes for the alpha 1A subunit of the neuronal voltage-
dependant P/Q-type calcium channel.
Ion channel genes play a critical role in normal func-
tioning of the central nervous system and neuromuscular
pathways. Functional studies have shown that FHM muta-
tions can lead to both gain and loss of  function of
P/Q-type calcium channels, all of which affect the physio-
logical functioning of the channels in a variety of ways
(Hans et al., 1999). Electrophysiological studies have
shown that either an increased or decreased influx of Ca2+
ions into cells caused by mutations in the CACNA1A gene
has an effect on the depolarized state of cells (Wieser,
2003). It has been shown that FHM1 mutations can
produce gain-of-function Ca(v)2.1 channels and, as a
result, initiate cortical spreading depression, which is the
phenomenon thought to underlie migraine aura. The
increased activity of the Ca(v)2.1 channel facilitates
increased Ca(v)2.1-dependant neurotransmitter release
from cortical neurons, in particular, glutamate (D’Onofrio
et al., 2009). A large amount of phenotypic heterogeneity
of clinical symptoms is still observed, which is indicative
of the complexity and variability of FHM1 (Wieser, 2003). 
Current diagnostic protocol for FHM involves analysis
of patient information by a clinician, according to criteria
specified by the Headache Classification Subcommittee of
the International Headache Society (Olesen, 2004).
Suspected cases are then referred for molecular diagnosis
by mutation analysis. Treatments such as administration
of Triptans or β-blockers are commonly used approaches
to treat common migraine and can also be used to treat
FHM sufferers, but have limited success, depending on the
individual (Arttoa, 2007; Ferrari, 2001). Other drugs used
to treat hemiplegic migraines include verapamil, acetazo-
lamide, ibuprofen, and calcium channel blockers. Most of
these treatments were originally designed to target differ-
ent disorders such as epilepsy, high blood pressure, cardiac
arrhythmia, and glaucoma. Any medications that constrict
arteries need to be avoided because this increases the risk
of stroke. FHM and migraine with aura sufferers are
already at an elevated risk for stroke, and drugs targeting
high blood pressure can aggravate this predisposition
(Diener & Kurth, 2011). For the most part, treatments are
still predominantly focused on alleviating symptoms, and
the development of new therapeutics targeting specific
pathways, especially those involving FHM, are needed.
Materials and Methods
Patients
Since beginning diagnostic processing in 1999, the
Genomics Research Clinic at Griffith University (Gold
Coast campus) has tested 587 patients for FHM, cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL), and episodic ataxia
type II (EA2)-causative mutations. DNA testing was
undertaken at the request of clinical neurologists around
Australia. These neurologists requested testing for FHM1
because, in each case, they had patients with symptoms
suggestive of FHM. The DNA testing was requested to
help to confirm or aid in a diagnosis. Clinical notes indi-
cated that 25 patients, or 14.9 % of patients, had a family
history of  FHM-related symptoms in other family
members. For the other cases, no familial FHM references
were recorded. Medical histories were noted in each case
and are summarized in Table 1. Of the 587 patients, 168
were tested for FHM1, FHM2, FHM3, or a combination
thereof. Because the majority (50%) of all known FHM
causative mutations are harbored in the CACNA1A gene,
this is the first test done and, therefore, all 168 patient
samples underwent CACNA1A mutation testing. All
mutations were noted and polymorphisms were recorded. 
Molecular Analysis
A blood sample was taken from each patient, and whole
DNA was extracted using a standard salting out proce-
dure. DNA was then quantified and normalized to a
concentration of 20 ng/µl. Exons 4,5,16,17, and 36 of
CACNA1A were amplified using AmpliTaq Gold DNA
polymerase (Applied Biosystems). Standard National
Association of Testing Authorities protocol for FHM1
testing was followed, including the use of recommended
primers and thermocycling conditions. 
The forward and reverse primers for exon 5 in which 
the novel mutation was found are as follows: 
forward 5’CTTGGTGGCGGGGTTT3’ and reverse
5’CTGCCTAATCCTCCCAAGAG3’. Following amplifica-
tion, post polymerase chain reaction products were run on
an agarose gel to check for sufficient amplification and
DNA quality. Then an ExoSap cleanup step was done,
before big dye termination sequencing on an ABI 3130
Genetic Analyser. Both the sense and antisense strands
were sequenced. Chromas was used to view and interpret
sequencing results. All polymorphisms and mutations
were reported.
Results
Of a total 168 patient samples tested for FHM1, 7 (4.43%)
tested positive for a single mutation in the CACNA1A
gene. Five of the mutations were found in exon 5, one
mutation in exon 16, and one in exon 17. The serine to
leucine mutation (Ser218Leu) occurred most frequently,
accounting for 57% of the positive results. Each of the
other mutations was found only once in the patient
cohort. One of these mutations, (Pro225His), has never
been reported previously. Table 1 summarizes the details
and frequency of each mutation found. In addition, four
polymorphisms were noted in other samples. The most
frequently occurring polymorphism that was found is sit-
uated in exon 16 (rs 16016) and was detected in 14.88% of
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the patient samples. The other polymorphisms were found
only in single patients, except for rs17846942, which was
detected in two sisters. All polymorphisms that were
detected are heterozygous and nonsynonomous. They are
summarized in Table 2.
Positive Mutation Results
The Pro225His mutation was identified in an 8-year-old
female patient. The patient was born prematurely (29
weeks gestation), presented with developmental delay,
speech and spacial sense impairment, poor concentration,
and epilepsy. Prior to the FHM test, no formal diagnosis
had been made. However, in addition to these symptoms,
the patient had at least four seizures that started with a
headache and progressed to right-side twitching and then
a generalized clonic seizure. This is the first report of this
mutation in a patient with FHM symptoms. There was
also a strong family history of a similar syndrome. The
patient’s mother has epilepsy and learning difficulties and
has been diagnosed with FHM1. She suffered a stroke at
age 11 years. The patient’s grandmother had seizures as a
neonate, and the patient’s brother had epilepsy as a child.
Discussion
Our studies investigating 168 patients with potential FHM
symptoms have identified six previously reported amino
acid-changing mutations in the CACNA1A gene, and a novel
mutation in an 8-year-old female patient. This is the first
report of this mutation in a patient with FHM symptoms. It
is unknown at what frequency this novel Pro225His muta-
tion occurs in patients or in the population. To date, 21
known causative missense mutations are associated with
FHM1 (de Vries et al., 2009). The most prevalent of these is a
threonine to methione substitution at amino acid position
666 in exon 16 (Barrett, Cao, & Tsien, 2005), which has been
reported in many previous FHM studies (Ducros et al., 1999;
Ophoff et al., 1996). This mutation was detected only once in
our patient cohort. Other frequently reported mutations
include Arg192G, Ser218Leu, and Arg583Gln (Chan et al.,
2008; Ducros et al., 1999; Ducros et al., 2001; Kors et al.,
2001; Ophoff et al., 1998). The Ser218Leu mutation was the
one found most frequently in our patient cohort and
accounted for 57% of positive results. This mutation was
originally reported by Curtain, et al. (2006) as part of previ-
ous investigative work in our patient cohort. The remaining
previously reported mutation that we found was the
Val714Ala change. This mutation has been published in at
least two previous FHM studies (Ophoff et al., 1996; 1998).
Proline is a nonpolar, slightly alkaline amino acid with
an aliphatic side chain. The cyclic structure of Proline gives
its backbone dihedral angle an approximately −75ºangle,
which results in an exceptional conformational rigidity,
compared to other amino acids. Proline acts as a structural
disruptor in the middle of regular secondary structure ele-
ments such as alpha helices and beta sheets, and is
commonly found in turns (Osvath & Gruebele, 2003).
Histidine is a polar, strongly alkaline amino acid with an
aromatic imidazole ring (Kopple & Swendseid, 1975). These
two amino acids have drastically different chemical proper-
ties, thus a proline to histidine change in a tertiary protein
structure could potentially disrupt protein function,
depending on the domain in which the substitution occurs.
The novel mutation detected in our 8-year-old patient
occurs at amino acid position 225 of the CACNA1A
protein. This change is positioned in a highly conserved
intracellular loop of the alpha-1A subunit that can be
viewed in the Swiss-Model Repository (Kiefer, Arnold,
Künzli, Bordoli, & Schwede, 2009; Kopp & Schwede, 2004).
The well-known S218L mutation occurring in the same
protein domain has been reported in two patients from a
family with extreme FHM, and in 1 patient whose parent
had FHM and whose family suffered from various neuro-
logic abnormalities (Kors et al., 2001). The replacement of a
hydrophilic serine for a hydrophobic leucine at residue 218
in the highly conserved intracellular loop was suggested by
the authors as a pathogenic change causing ionic perturba-
tion, as a result of inappropriately depolarized ion channels.
Even though the novel mutation identified occurs in a
highly conserved domain of the CACNA1A protein, func-
tional studies will need to be conducted to confirm if the
TABLE 1
Summary of Patient Information
Diagnostic Patients Age Reported family history Reported Symptoms
168 Range 25 (14.9%) Periodic ataxia 15 (8.9%)
91years–1year old Hemiplegia 37 (22.0%)
Median 40years Migraine 56 (33.3%)
Concussion/loss of 
consciousness/coma 9 (5.4%)
Stroke 4 (2.4%)
Paroxysmal vertigo 4 (2.4%)
Seizures/epilepsy 9 (5.4%)
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amino acid change is pathogenic. A recent study found a
surprisingly high level of missense single-nucleotide poly-
morphisms (SNPs) in ion channel genes in both affected
patients and healthy controls, and it is possible that this may
be a different mutation accounting for the disease pheno-
type of the patient (Klassen et al., 2011).
A number of common polymorphisms are also known
to occur in the CACNA1A gene. The known nonpatho-
genic polymorphisms are summarized in Table 2. The
most frequent polymorphism found in our patient cohort
is rs16016, which is estimated to occur in frequencies from
12% to 16% in Caucasian populations (NCBI, 2011). This
polymorphism was found in almost 15% of our patient
samples, but given how common rs16016 is in the
European population, it unlikely to have any association
with FHM, EA2, or spinocerebellar ataxia type 6 (SCA6).
Similar frequencies of rs16016 were found in previous
FHM studies, and this particular SNP has been reported as
being non pathogenic (Ducros et al., 1999; Ophoff et al.,
1996). Three other polymorphisms were found in our
patient cohort, as illustrated in Table 1. Each polymor-
phism was detected in only one patient, except for
rs17846942, which was found in two sisters. rs41276894
has a reported minor allele frequency of 0.6% in the
Caucasian population and is considered to be a rare
variant (NCBI, 2011). It has been reported to occur in fre-
quencies of up to 2% in previous studies, and is also
considered to be nonpathogenic (Ducros et al., 2001;
Ophoff et al., 1996). There is very little published informa-
tion available for the third polymorphism (5404-14C>T)
that was detected in our patient cohort. It has been
reported in the CACNA1A gene variation database, but it
is unknown at what frequency the detected polymorphism
occurs or what effect is has on protein function. Similarly,
little information is available about rs17846942. It has a
reported minor allele frequency of 6.3% in the Chinese
TABLE 3
Summary of Known Nonpathogenic Polymorphisms in CACNA1A
Exon DNA change Amino acid change Frequency (%) rs number Study in which first reported 
1 c.1-53_1-54insGGC No 0.04 — Battistini et al. (1999)
4 c.579G>A No 0.02 rs41276894 Ducros et al. (2001); 
Ophoff et al. (1996)
6 c.876A>G No 0.07 rs16006 Ducros, Joutel, et al. (1999); 
Ophoff et al. (1996)
9 c.1199-31A>G No 0.6 rs16008 Carrera et al. (1999)
11 c.1360G>A No 0.02 rs41276886 Cricchi et al. (2007); 
Ophoff et al. (1996)
16 c.2094G>A No 0.12 rs16016 Ducros, Joutel, et al. (1999); 
Ophoff et al. (1996)
19 c.2978A>T No 0.62 rs16023 Carrera et al. (1999)
19 c.3060G>A No 0.62 rs16025 Carrera et al. (1999)
20 c.3313G>A No 0.25 rs16027 Ducros, Joutel, et al. (1999)
20 c.3549C>T No 0.02 rs16029 Carrera et al. (1999)
39 c.5742C>T No 0.006 rs16044 Carrera et al. (1999)
Note: adapted from http://grenada.lumc.nl/LOVD2/FHM/variants.php?select_db=CACNA1A&action=search_unique&search_pathogenic_=-(CACNA1A 
variation database)
TABLE 2
Summary of Identified Mutations and Polymorphisms in our Patient Cohort
Mutations
No. Exon Nucleotide change Amino acid change No. positive samples 
1 5 653 C>T Ser218Leu 4
2 5 674 C>A Pro225His 1
4 16 1997 C>T Thr666Met 1
5 17 2141 T>C Val714Ala 1
Polymorphisms
No. Exon/Intron Nucleotide change rs number No. positive samples
1 Exon 16 2094G>A rs 16016 25
2 Exon 36 5404-14C>T — 1
3 Exon 4 579G>A rs41276894 1
4 Intron 3 540-30C>G rs17846942 2
and Japanese population and thus is considered a
common polymorphism (NCBI, 2011). Because it is so
common, it is extremely unlikely that it has a pathogenic
effect. Other common previously detected polymorphisms
are listed in Table 2. Of note are two polymorphisms that
are particularly common in the Italian population
(rs16023 and rs16025) and occur in frequencies of up to
62% (Carrera, Stenirri, Ferrari, & Battistini, 2001).
While FHM is inherited in a dominant Mendelian
fashion, common migraine is a complex polygenic disease.
As with other complex diseases, it is hypothesized that
many small genetic variants interacting with the environ-
ment have an additive effect to bring about the condition
(Maher & Griffiths, 2011). It is unknown exactly which
commonly occurring polymorphisms, or combination
thereof, have an underlying effect on migraine pathogene-
sis, and it is therefore important to analyze all variants
occurring in potential candidate genes and/or pathways.
Even seemingly nonpathogenic polymorphisms should
not be overlooked. A study by D’Onofrio et al. (2009)
found that the interplay of two SNPs may have an influ-
ence on the P/Q-type channel function in several subtypes
of migraine, although they do not play a role in FHM.
Only when data from patients suffering from migraine
with aura and migraine without aura were pooled were
results found to be significant. This suggests that there is
some overlap between different migraine subtypes .The
general pathways in which the FHM genes are involved
remain good candidates for studies trying to elucidate the
pathophysiology of common migraine, and should be
examined in detail.
Conclusion
This study reports the detection of a novel mutation in the
CACNA1A gene. Because not all of the causative genes for
FHM or for common migraine are known, it is essential to
continue investigating novel mutations and variants. New
information will allow for the production of more accurate
diagnostic procedures and also aid the development of new
therapeutic agents for the treatment of FHM (Fernandez,
Colson, & Griffiths, 2007). The general pathways in which
the FHM genes are involved may also be good candidates
for studies trying to elucidate the pathophysiology of
common migraines (Maher & Griffiths, 2011). Therefore,
further research into FHM could also aid in better thera-
peutics for the treatment of common migraine.
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